Articles tagged with Cell Therapies
Researchers found that bone marrow mononuclear cell infusion in children within 48 hours of severe traumatic brain injury reduced intensive care needs and preserved white matter. The treatment also enhanced connectivity in the corpus callosum, a midline structure in the brain.
Researchers at St. Jude Children's Research Hospital have developed a molecular glue that sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to its destruction. The compound, SJ3149, displays broad anti-cancer activity and may have clinical utility as an alternative to conventional small molecule inhibitors.
A study by the University of Sheffield found that breast cancer cells take advantage of nutrients in the extracellular matrix when faced with nutrient starvation. The cells use an ingestion process called macropinocytosis to consume the matrix, breaking it down into energy-releasing substrates.
Researchers studied the effects of resveratrol on circadian clock gene expression in young and older human adipose-derived progenitor cells. They found increased levels of some components in older-APCs compared to young-APCs, but also observed gained rhythmicity of some components after resveratrol treatment.
Researchers from Tokyo University of Science discovered that manipulating polyamines enhances the functional profiles of monoclonal antibodies. The study found that controlling polyamine levels increases IgG galactosylation, leading to improved therapeutic efficacy.
The Organoid group at the Hubrecht Institute produced the first organoid model of the human conjunctiva, which functions like real human conjunctiva. The researchers discovered a new cell type called tuft cells that become more abundant under allergy-like conditions and play a role in eye's reaction to allergies.
Researchers at the University of Miami Miller School of Medicine have discovered that glioblastoma cells can mimic healthy neurons, evading drugs and immune systems. They identified key enzymes and protein modifications, including BRAF, which shows promise as a potential therapy target.
A new special issue of Calcified Tissue International & Musculoskeletal Research sheds light on sarcopenia's pathogenesis, clinical implications, and therapeutic targets. Researchers have made significant progress in evaluating, managing, and developing interventions for this condition.
Researchers unveiled a previously unknown effect of PG545 in ovarian cancer cells, inducing DNA damage and promoting autophagic degradation of RAD51. This breakthrough could aid in selecting the most appropriate treatments for ovarian cancer patients with PARPi resistance.
Graphene quantum dots have been designed to enhance catalytic performance using a diatomic doping strategy, resulting in impressive peroxidase-mimicking activity. This metal-free nanozyme has shown high efficacy in inducing apoptosis and ferroptosis of cancer cells with minimal side effects.
Researchers discuss clonal hematopoiesis, a condition where cells harbor somatic mutations, and its association with aging, solid tumors, and treatment outcomes. Emerging evidence suggests that CH may play a role in cancer development and survival.
Researchers found that specific microbes in the gut reduce graft versus host disease after stem cell transplantation. Patients with low microbial metabolite risk index had better survival rates, fewer graft vs. host reactions, and reduced relapses.
A pioneering study published in The American Journal of Pathology reveals the cytoprotective and proregenerative effects of neuropeptide α-MSH in promoting corneal healing after eye injury. The treatment has shown impressive therapeutic potential in reducing the need for corneal transplants.
A study found that patients with refractory large B-cell lymphoma who received bendamustine before CAR T-cell therapy had a shorter progression-free survival and overall response rate compared to those who did not receive bendamustine. The use of bendamustine should be avoided in these patients when possible.
Researchers identified Elovanoid-34, a molecule that modulates the activity of TXNRD1 protein, which regulates antioxidant defenses. This discovery opens new therapeutic avenues for degenerative brain and eye diseases, as well as promoting healthy aging.
Researchers discovered a novel therapeutic target BAMBI that suppresses immune cells, reducing the effectiveness of radiation therapy and inducing therapy resistance in cancer patients. BAMBI's expression is associated with improved survival rates, suggesting it as a promising approach to overcome radiation therapy resistance.
Researchers have identified promising treatment candidates for morphine tolerance and cancer, as well as a biomarker for kidney injury. A monoclonal antibody targeting the mu-opioid receptor has been shown to alleviate morphine tolerance and physical dependence, while inducing excessive mitochondrial fission in tumor cells. Additionall...
Researchers successfully tested a simple intervention that boosts T cells' ability to destroy human tumors using fenofibrate. The treatment improves the efficacy of CD8+ T cell therapy for melanoma by providing an alternative energy source, thereby enhancing cancer-killing power.
A novel synthesis method enables easy linkage of therapeutic oligonucleotides to peptide markers, streamlining the process and making it more accessible and cost-effective. This breakthrough has the potential to produce more effective and targeted RNA-based drugs.
Researchers investigated mechanisms of NK cell-mediated killing in various types of blood cancers, uncovering genes involved in sensitivity and resistance to NK cell therapies. The study aims to develop new personalized immunotherapies for improved cancer treatment outcomes.
A comprehensive review of targeted therapies for lupus nephritis discusses the challenges of current treatments and proposes strategies to overcome obstacles. Recent advancements in B-cell targeting and alternative approaches such as CAR-T cells are highlighted.
A U of M-led study introduces an innovative genetic engineering method that avoids cost and safety concerns associated with viral vectors. The method combines CRISPR-Cas9 precision genome editing and a novel DNA integration mechanism, integrating large DNA sequences into human T-cells with high efficiency.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
A recent study found that human induced pluripotent stem cell-derived cardiomyocytes interact negatively with myofibroblasts, leading to electrical instability and arrhythmogenic potential. Blocking Interleukin-6 signalling reduced these negative effects, suggesting a promising therapeutic strategy for safe regenerative treatments.
A phase 1 clinical trial demonstrates the efficacy of third-generation anti-CD19 CAR T-cells in treating relapsed or refractory B-cell non-Hodgkin lymphomas without causing neurotoxicity. The study also shows a robust response rate of 52% and improved safety profile compared to previous CAR T-cell therapies.
A novel study has implicated granulocyte colony-stimulating factor (G-CSF) in both bronchopulmonary dysplasia and retinopathy of prematurity, making it a promising therapeutic candidate. G-CSF deficiency was shown to protect against these diseases, suggesting wide-ranging protection.
A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...
Researchers are shedding light on the molecular mechanisms underlying HIV replication and viral integration, opening new avenues for tackling the virus. Discoveries suggest that targeting the cell nucleus and harnessing innate immunity may be key to blocking viral replication and persistence.
Researchers found that BCMA-positive extracellular vesicles (EVs) in plasma levels correlated with myeloma patient responses to belantamab-mafodotin therapy. High EV levels preceded FLC progression and were associated with mafodotin-induced eryptosis.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
Researchers found that probiotics can limit CRC-promoting bacteria, rebalance the microbial profile, and induce targeted cancer cell death. Postbiotics derived from probiotic bacteria have also been shown to prevent CRC by limiting tumor proliferation and modulating the balance of anti-apoptotic and pro-apoptotic factors.
Researchers discovered that RvD2, a specialized proresolving lipid mediator, can alleviate established liver scarring or fibrosis. Treatment with RvD2 improved liver histopathology and increased bone marrow and blood monocytes.
Researchers at Tohoku University found that Bergmann glial cells in the cerebellar vermis regulate the volume of aggression in mice. The study suggests that adjusting glial activity in the cerebellum could lead to therapeutic strategies for managing anger and aggression.
A study by the University of the Basque Country uses game theory to establish that tumours with less cellular heterogeneity are more aggressive. The work suggests a fresh theoretical approach for new therapeutic strategies, focusing on preserving high intratumour heterogeneity.
Scientists at St. Jude Children's Research Hospital created a highly adaptable system to improve the safety and efficacy of immunotherapy for solid tumors. By adding modular chimeric cytokine receptors to CAR T cells, the therapy can target multiple types of cancer without generating significant toxicity.
A team of researchers from Texas A&M University is developing a low-cost, safe, and controlled cancer treatment using programmable bacteria. The $20 million project aims to create an efficient bacterial therapeutic that can target cancer cells with high precision, reducing side effects and costs.
A novel contamination-detection method enables faster and safer T-cell therapy production, reducing the risk for patients and speeding up treatment. The method uses cutting-edge technology to identify harmful microorganisms within 24 hours.
Researchers developed novel small molecule inhibitors of CPSF3, a key regulator of transcription termination in ovarian cancer cells. These inhibitors exhibited potent antiproliferative effects and suppressed tumor growth in vivo.
Scientists at St. Jude Children's Research Hospital validated GRP78 as a promising but complex target for CAR T-cell immunotherapy. However, they discovered that some tumors trick the immune cells into expressing GRP78, turning off their own cancer-killing ability.
Researchers investigate nanoparticles for cancer treatment, hoping to reduce side effects and improve efficacy. La-Beck's lab aims to understand the body's interaction with nanoparticles and their impact on tumor growth and immune responses.
A recent study by Harvard researchers provides an engineering approach to understanding the failure of macrophages in cancer therapies. The team found that different phenotypes exhibit different penetration into tumors, with M0 macrophages showing improved transport efficiency.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
A new study suggests that a PCSK9 inhibitor given every 1-3 months may effectively lower bad cholesterol levels in people with non-genetic hypercholesterolemia. The medication, recaticimab, showed similar effectiveness and safety as other PCSK9 inhibitors when administered less frequently.
A novel device, ecO2, produces oxygen at the site to keep cells alive for up to a month in vitro or weeks in vivo. This innovation improves the outcomes of cell-based therapies for diseases and injuries by increasing metabolic demand.
Researchers at Duke University developed a CRISPR-based platform to identify genes that improve T-cell therapies for cancer treatment. They discovered BATF3, a single master regulator of the genome, which reprograms thousands of genes in T cells and greatly enhances cancer cell killing.
Researchers have identified a crucial biological trigger of Huntington's disease, finding that methylation converts an important protein into waste. By targeting this process, they may develop effective therapies for other neurodegenerative diseases.
Researchers analyzed over 314,000 cells from rheumatoid arthritis tissue to define six types of inflammation involving diverse cell types and disease pathways. The findings shed new light on the cellular causes of RA, potentially informing targeted and effective therapeutic approaches.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
A new study reveals a link between the removal of the FGFR1 protein's extracellular domain and a significant decrease in tumour volume. This finding offers a potential new avenue of treatment for patients with squamous cell carcinoma of the lungs, who have shown limited success with current therapies.
Researchers found that a high-sugar diet causes insulin resistance in the brain, reducing its ability to remove neuronal debris and increasing the risk of neurodegenerative diseases. This study provides insight into how obesity-inducing diets contribute to disease risk.
Researchers have discovered that mitochondrial respiration failure leads to genetic and metabolic reprogramming of T cells, causing their functional exhaustion. However, pharmacological or genetic optimization of cellular metabolism can increase T cell longevity and functionality.
Mutations in the PIK3CA gene lead to elevated production of the PI3Ka protein, found in approximately 40% of hormone receptor-positive breast cancers. Next-generation PI3Kalpha inhibitors targeting a different region of the mutant protein show promise in overcoming resistance.
Researchers found that FAAH inhibition reduced breast cancer growth in immunodeficient mice and induced apoptosis of breast cancer cells. The combination of FAAH inhibitors and endocannabinoids was the most effective treatment approach.
Researchers have made significant progress in understanding a pathway contributing to liver fibrosis. Paxillin has been found to play a key role in the activation of hepatic stellate cells, leading to excessive extracellular matrix production and scarring. This discovery holds promise for developing new treatments for liver fibrosis.
Researchers have discovered a novel biomarker that enables the evaluation of near-infrared photoimmunotherapy (NIR-PIT) treatment success. The biomarker uses microbubbles to track tumor vessels and measure the effectiveness of NIR-PIT, which combines antibodies and near-infrared light to destroy cancer cells.
A new tool has been developed to rapidly grow cancer-killing white blood cells, called T cells, which could advance the availability of immunotherapy. The bioreactor is 30% faster than current technologies and can be self-contained in a sterile cabinet.
Researchers have developed a novel approach, REVeRT, to efficiently transport large genes using dual AAV vectors at the transcript level. This new method offers increased efficiency, fewer side effects, and greater flexibility compared to existing strategies.
A collaborative study has identified key epigenetic targets for treating hepatoblastoma, the most common childhood liver cancer. The research found that the enzyme histone-lysine methyltransferase G9a plays a crucial role in epigenetic regulation and is a promising therapeutic target.
Researchers developed a novel 'pseudo cell' formulation using self-healing microcapsule-loading exosomes to treat diverse vitreoretinal diseases. The treatment demonstrated therapeutic benefits in both murine and nonhuman primate models, offering potential for improved patient compliance.